The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma

R. Dummer; K. Flaherty; R. Kefford; P. A. Ascierto; L. Moutouh-de Parseval; E. Wasserman; D. Schadendorf

The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma

R. Dummer, K. Flaherty, R. Kefford, P. A. Ascierto, L. Moutouh-de Parseval, E. Wasserman, D. Schadendorf

Research output: Contribution to journal › Meeting abstract

Original language	English
Article number	150 (PP17)
Pages (from-to)	67-68
Number of pages	2
Journal	British Journal of Dermatology
Volume	171
Issue number	Supplement 4
Publication status	Published - Sept 2014
Externally published	Yes
Event	15th World Congress on Cancers of the Skin - Edinburgh, United Kingdom Duration: 3 Sept 2014 → 6 Sept 2014

Cite this

Dummer, R., Flaherty, K., Kefford, R., Ascierto, P. A., Moutouh-de Parseval, L., Wasserman, E., & Schadendorf, D. (2014). The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma. British Journal of Dermatology, 171(Supplement 4), 67-68. Article 150 (PP17).

@article{5a69010a6700408fb0c2d82c57bda005,

title = "The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma",

author = "R. Dummer and K. Flaherty and R. Kefford and Ascierto, \{P. A.\} and \{Moutouh-de Parseval\}, L. and E. Wasserman and D. Schadendorf",

year = "2014",

month = sep,

language = "English",

volume = "171",

pages = "67--68",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "Supplement 4",

note = "15th World Congress on Cancers of the Skin ; Conference date: 03-09-2014 Through 06-09-2014",

}

The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma. / Dummer, R.; Flaherty, K.; Kefford, R. et al.
In: British Journal of Dermatology, Vol. 171, No. Supplement 4, 150 (PP17), 09.2014, p. 67-68.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma

AU - Dummer, R.

AU - Flaherty, K.

AU - Kefford, R.

AU - Ascierto, P. A.

AU - Moutouh-de Parseval, L.

AU - Wasserman, E.

AU - Schadendorf, D.

PY - 2014/9

Y1 - 2014/9

UR - https://doi.org/10.1111/bjd.13282

M3 - Meeting abstract

C2 - 25182344

SN - 0007-0963

VL - 171

SP - 67

EP - 68

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - Supplement 4

M1 - 150 (PP17)

T2 - 15th World Congress on Cancers of the Skin

Y2 - 3 September 2014 through 6 September 2014

ER -

The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma

Other files and links

Cite this